Tag - CAMP

CAMP4 Therapeutics (NASDAQ:CAMP) has announced that three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs, and shared favorable safety and pharmacokinetics data from the...